Ranked #13 in the competitive Concentrates category, PHANT faces significant challenges, trailing leaders like ENDGAME and BOXHOT. It slipped from #9 to #13 in the past year, intensifying competitive pressure.
SKU View
Top Selling ProductsJun 2026
Top products for Jun 2026 with sales and momentum indicators.
A staggering 67.0% drop in year-over-year sales marks a critical challenge for PHANT. Despite this, a recent 9.9% uptick in the last three months indicates a potential recovery phase for this premium cannabis brand.
Categories
ConcentratesVapesPre-RollsFlower
Top Category: Concentrates
Price Tier: Premium
States Active: 1
74.4%
Concentrates dominate at 58.6% of sales, but have dipped 44.4% YoY. Vapes hold 24.7% with a sharp decline of 79.5%, while Flower and Edibles show even steeper drops, underscoring category volatility.
Category
Sales Share
Avg Price
YoY
Concentrates
57.0%
$32.8
16.5%
Vapes
26.3%
$36.02
56.0%
Pre-Rolls
10.1%
$20.97
34.5%
Flower
6.6%
$48.34
47.1%
Trend View
Market Insights SnapshotJun 2026
24-Month Trend
Average Price
$31.98
YoY Sales Trend
37.6%
2Y Sales Trend
74.4%
Category Breakout
Category
Sales Share
Avg Price
YoY
Concentrates
57.0%
$32.8
16.5%
Vapes
26.3%
$36.02
56.0%
Pre-Rolls
10.1%
$20.97
34.5%
Flower
6.6%
$48.34
47.1%
State Rank Table
State
Concentrates
Vapes
Pre-Roll
Flower
British Columbia
13
⊖
⊖
⊖
PHANT's strongest presence is in British Columbia, representing 100.0% of its sales in a single state, highlighting a concentrated geographic strategy.
